- Dual-pathway GH secretagogue research (GHRH + ghrelin receptor)
- Pulsatile growth hormone release studies
- Selective GH signaling with minimal off-target hormonal effects in studies
- Metabolic regulation and body composition pathway studies
- Single-vial 5mg + 5mg blend for combined-secretagogue study designs
Overview
What is CJC-1295 + Ipamorelin Blend?
The CJC-1295 + Ipamorelin blend is a research compound pairing a growth hormone-releasing hormone (GHRH) analogue with a selective ghrelin receptor (GHS-R1a) secretagogue, at 5mg of each per 10mg vial. It is used to study combined growth hormone pathway signaling in vitro. Supplied for laboratory research use only.
Blend Composition
- CJC-1295 (No DAC) · GHRH Analog
- 5mg
- Ipamorelin · Ghrelin Agonist
- 5mg
Mechanism in research
How CJC-1295 + Ipamorelin Blend is studied
In published research the two compounds engage distinct receptors that converge on growth hormone release from pituitary somatotrophs. CJC-1295, a GHRH analogue, has been reported to produce sustained increases in growth hormone and IGF-I in healthy adults, while Ipamorelin was characterized as the first selective growth hormone secretagogue, stimulating GH release without significantly affecting ACTH or cortisol. The blend is studied for how these GHRH and ghrelin-receptor pathways may interact; combined mechanisms and outcomes in humans are not established.
Reported targets & pathways
- GHRH receptor
- Ghrelin / GHS-R1a receptor
- Pituitary somatotroph GH release
- IGF-1 axis
Reference data
CJC-1295 + Ipamorelin Blend specifications
- Composition
- 5mg CJC-1295 (No DAC) + 5mg Ipamorelin
- CJC-1295 class
- Synthetic GHRH(1-29) analogue (modified, No DAC)
- Ipamorelin class
- Synthetic pentapeptide GH secretagogue (GHRP)
- Total amount per vial
- 10mg co-lyophilized blend
- Appearance
- White lyophilized powder
- Solubility
- Soluble in bacteriostatic water
- Purity
- 99.4% (HPLC)
Research applications
Where CJC-1295 + Ipamorelin Blend is used in research
Areas of study described in the published literature. Listed for research reference only.
Growth hormone release
Studied for the combined effect of GHRH and ghrelin-receptor stimulation on pulsatile GH secretion.
Metabolic regulation
Used in research on the GH/IGF-1 axis and downstream metabolic and body-composition endpoints.
Receptor pharmacology
Applied to investigate signaling at the GHRH receptor and the ghrelin/GHS-R1a receptor in parallel.
Secretagogue selectivity
Explored in study designs comparing selective GH release against off-target pituitary hormone effects.
Selected research
Published studies on CJC-1295 + Ipamorelin Blend
Peer-reviewed references for further reading. Findings describe in-vitro and animal research; mechanisms and outcomes in humans are not established.
Journal of Clinical Endocrinology & Metabolism · 2006
Reported that subcutaneous CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-I in healthy adults.
European Journal of Endocrinology · 1998
Characterized Ipamorelin as the first selective growth hormone secretagogue, reporting GH release comparable to GHRH without significant ACTH or cortisol elevation.
Comparison
CJC-1295 + Ipamorelin vs the standalone compounds
| Blend | CJC-1295 (No DAC) | Ipamorelin | |
|---|---|---|---|
| Receptor target | GHRH + ghrelin (GHS-R1a) | GHRH receptor | Ghrelin / GHS-R1a |
| Class | GHRH analogue + GHRP | GHRH(1-29) analogue | Selective GH secretagogue |
| Per-vial amount | 5mg + 5mg (10mg) | 5mg / 10mg | 10mg |
| Research focus | Combined GH pathway | Pulsatile GH release | Selective GH release |
Quality
Independently verified, batch by batch
Tested every batch
Every batch of CJC-1295 + Ipamorelin Blend is independently analyzed by a third-party laboratory before it is released.
HPLC + mass spectrometry
Identity and purity are confirmed by HPLC with mass spectrometry. This batch is verified to 99.4% purity.
Certificate of analysis
A certificate of analysis is produced for every batch, and all lab results are published on our website.
Reviews
What researchers say about CJC-1295 + Ipamorelin Blend
blend assay matched
ran the cjc + ipamorelin blend on our hplc and both came back in spec, 5mg each like listed. been using the standalone cjc from miro for a while so figured id try the combined vial. saves us a step in the lab
quick to toronto
8 days to toronto and packaging was solid. dissolved clean for our GH pathway work, no complaints
good blend, minor note
ordered the cjc + ipamorelin for a secretagogue project. purity testing was fine on both compounds and the price beats what we were quoted elsewhere. only thing is the single combined vial means you cant adjust the ratio if your protocol needs something other than 5 and 5. for our use it was fine though
reordering
second order of the blend to abu dhabi, consistent quality and the COA matched what we got on our end
CJC-1295 + Ipamorelin Blend FAQ
Shipping CJC-1295 + Ipamorelin Blend to India?
Free shipping, UPI payments, INR pricing, and 7-14 day tracked delivery.
Related Products
Retatrutide
99.62% pureTriple agonist peptide targeting GLP-1, GIP, and glucagon receptors for metabolic and obesity research.
Tesamorelin
99.20% pureGHRH analogue that stimulates growth hormone release, researched for metabolic regulation and body composition studies.
MOTS-c
99.79% pureMitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and cellular homeostasis.
CJC-1295 (No DAC)
99.60% pureHigh-purity (99.60%) CJC-1295 without DAC research peptide. GHRH analogue for growth hormone secretion, pulsatile GH release, and metabolic pathway studies.
